Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer - PubMed (original) (raw)
Clinical Trial
Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer
Matthias Schuetz et al. Acta Oncol. 2010 Oct.
Abstract
Background: The aim of this pilot study was to assess tumour hypoxia in patients with cervical cancer before, during and after combined radio-chemotherapy and Magnetic Resonance Imaging (MRI) guided brachytherapy (BT) by use of the hypoxia Positron Emission Tomography (PET) tracer (18)F-fluoroazomycin-arabinoside ((18)FAZA ).
Material and methods: Fifteen consecutive patients with locally advanced cervical cancer referred for definitive radiotherapy (RT) were included in an approved clinical protocol. Stage distribution was 3 IB1, 1 IB2, 10 IIB, 1 IIIB, tumour volume was 55 cm(3) (+/- 67, SD). Dynamic and static (18)FAZA -PET scans were performed before, during and after external beam therapy (EBRT) and image guided BT +/- concomitant cisplatin. Dose was prescribed to the individual High Risk Clinical Target Volume (HR CTV) taking into account the dose volume constraints for adjacent organs at risk.
Results: Five patients had visually identifiable tumours on (18)FAZA -PET scans performed prior to radio-chemotherapy and four patients before brachytherapy. One of five (18)FAZA PET positive patients had incomplete remission three months after RT, one had regional recurrence. Four of ten (18)FAZA-PET negative patients developed distant metastases. The one patient with incomplete remission received 69 Gy (D90) in the HR CTV, whereas all other patients received mean 99 Gy (+/-12, SD).
Conclusion: PET imaging with (18)FAZA is feasible in patients with cancer of the uterine cervix. However, its predictive and prognostic value remains to be clarified. This applies in particular for the additional value of (18)FAZA-PET compared to morphologic repetitive MRI within the setting of image guided high dose radiotherapy which may contribute to overcome hypoxia related radioresistance.
Similar articles
- MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective.
Lindegaard JC, Fokdal LU, Nielsen SK, Juul-Christensen J, Tanderup K. Lindegaard JC, et al. Acta Oncol. 2013 Oct;52(7):1510-9. doi: 10.3109/0284186X.2013.818253. Epub 2013 Aug 21. Acta Oncol. 2013. PMID: 23962242 - Correlation analysis of [18F]fluorodeoxyglucose and [18F]fluoroazomycin arabinoside uptake distributions in lung tumours during radiation therapy.
Di Perri D, Lee JA, Bol A, Hanin FX, Janssens G, Labar D, Robert A, Sterpin E, Geets X. Di Perri D, et al. Acta Oncol. 2017 Sep;56(9):1181-1188. doi: 10.1080/0284186X.2017.1329594. Epub 2017 May 24. Acta Oncol. 2017. PMID: 28537761 - FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.
Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen BS, Toustrup K, Jakobsen S, Petersen J, Petersen H, Theil J, Nordsmark M, Overgaard J. Mortensen LS, et al. Radiother Oncol. 2012 Oct;105(1):14-20. doi: 10.1016/j.radonc.2012.09.015. Epub 2012 Oct 16. Radiother Oncol. 2012. PMID: 23083497 Clinical Trial. - Pilot study in the treatment of endometrial carcinoma with 3D image-based high-dose-rate brachytherapy using modified Heyman packing: clinical experience and dose-volume histogram analysis.
Weitmann HD, Pötter R, Waldhäusl C, Nechvile E, Kirisits C, Knocke TH. Weitmann HD, et al. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):468-78. doi: 10.1016/j.ijrobp.2004.10.013. Int J Radiat Oncol Biol Phys. 2005. PMID: 15890589 Review. - [Metabolic tailoring in radiotherapy for head and neck cancer].
Servagi-Vernat S, Giraud P. Servagi-Vernat S, et al. Cancer Radiother. 2014 Oct;18(5-6):565-71. doi: 10.1016/j.canrad.2014.05.011. Epub 2014 Aug 30. Cancer Radiother. 2014. PMID: 25179254 Review. French.
Cited by
- Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo.
Gammon ST, Pisaneschi F, Bandi ML, Smith MG, Sun Y, Rao Y, Muller F, Wong F, De Groot J, Ackroyd J, Mawlawi O, Davies MA, Gopal YNV, Di Francesco ME, Marszalek JR, Dewhirst M, Piwnica-Worms D. Gammon ST, et al. Cells. 2019 Nov 21;8(12):1487. doi: 10.3390/cells8121487. Cells. 2019. PMID: 31766580 Free PMC article. - Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.
Jacobson O, Chen X. Jacobson O, et al. Pharmacol Rev. 2013 Sep 24;65(4):1214-56. doi: 10.1124/pr.113.007625. Print 2013. Pharmacol Rev. 2013. PMID: 24064460 Free PMC article. Review. - Imaging tumour hypoxia with positron emission tomography.
Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, Domarkas J, Lord S, Baldry C, Gilbert FJ. Fleming IN, et al. Br J Cancer. 2015 Jan 20;112(2):238-50. doi: 10.1038/bjc.2014.610. Epub 2014 Dec 16. Br J Cancer. 2015. PMID: 25514380 Free PMC article. Review. - Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity.
Zheng J, Klinz SG, De Souza R, Fitzgerald J, Jaffray DA. Zheng J, et al. EJNMMI Res. 2015 Dec;5(1):57. doi: 10.1186/s13550-015-0135-x. Epub 2015 Oct 19. EJNMMI Res. 2015. PMID: 26481012 Free PMC article. - Advances in radiotherapy: from 2D to 4D.
Høyer M, Thor M, Thörnqvist S, Søndergaard J, Lassen-Ramshad Y, Paul Muren L. Høyer M, et al. Cancer Imaging. 2011 Oct 3;11 Spec No A(1A):S147-52. doi: 10.1102/1470-7330.2011.9036. Cancer Imaging. 2011. PMID: 22185864 Free PMC article. Review.